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In 1628, William Harvey published his epoch-making treatise 
“On  The  Motion  Of  The  Heart  And  Blood  In  Animals”. 
This  70-page booklet laid  the foundation  for  contemporary 
cardiology.  Since  then,  life  sciences  research  has  not  only 
facilitated the vigorous advances associated with the Industrial 
Technology  Revolution  Tidal  Wave  and  the  Information 
Technology Revolution Tidal Waves, but also paved the way 
for progress in the diagnosis and treatment of cardiovascular 
diseases  (CVD).  Time  witnessed  the  following  momentous 
milestones in cardiovascular medicine:
1.    The clinical application of aspirin and other anti-thrombocyte, 
cardiotonics, diuretics, angiotensin converting enzyme inhibitor 
(ACEI), beta blocker and statin class lipid-lowering medications 
has significantly reduced the risk of the CVD patients, greatly 
improved the symptoms and the quality of lives and distinctly 
ameliorated the prognosis of CVD patients.
2.    Implementation  of  accessory  examination  tools,  including  the 
stethoscope, electrocardiograph (ECG), modern high energy X-ray 
machines, echocardiography (Echo), nuclide scan, computerized 
tomography  (CT),  magnetic  resonance  imaging  (MRI),  and 
positron emission tomography (PET) has greatly enhanced our 
clinical diagnosis level of CVD.
3.    The  appearance  of  the  pacemaker,  implantable  converter 
defibrillator  (ICD),  coronary  angiography  (CAG),  stent  and 
the  drug-eluting  stent,  and  the  emergence  of  radio  frequency 
catheter ablation (RFCA) and percutaneous coronary intervention 
(PCI) technology have led us into a new era of Interventional 
Cardiology.
4.    Cardiopulmonary  bypass  technology,  coronary  artery  bypass 
grafting  (CABG)  technology,  heart  transplant  technology,  off 
pump-bypass  technology  and  the  new  generation  of  artificial 
heart development have all contributed to the improved precision 
of cardiac surgery techniques.
Building  on  the  brilliant  achievements  of  the  Industrial 
Revolution  and  Information  Technology  Revolution  Tidal 
Waves, we are moving towards the new era of a Life Science 
Technology Revolution Tidal Wave.
Today,  cardiology  is  advancing  in  genotype  –  phenotype 
association of cardiovascular diseases, the structure and function 
of ion channels, the upstream and downstream mediators of 
signal transduction pathways, and the regulation of myocyte 
proliferation and apoptosis.
The elucidation of the nitric oxide (NO) signal transduction 
pathway  and  the  determination  of  the  potassium  channel 
structure led to the recent choices of Nobel Prize laureates.
Stem Cell therapy is emerging as a hot topic in all kinds of 
cardiovascular disease congresses all over the world.
However, we are far from conquering the CVD. We are still 
faced with a more and more serious situation.
Because of the dramatic changes in lifestyle, increases in the 
aging population and because of striking changes in disease 
spectrum, since 1900, the morbidity and mortality rates of CVD 
have steadily increased at an alarming rate in the world. At the 
beginning of the 20th century, CVD accounted for less than 10 
percent of all deaths worldwide. At its end, CVD accounted for 
nearly half of all deaths in the developed world and 25 percent 
in the developing world.1
Today,  both  the  developed  countries  and  the  developing 
countries all over the world are challenged by the prevalence 
of CVD.
In the United States only, an estimated 80.7 million adults 
(one in three) have one or more types of CVD. CVD is the 
leading killer of both men and women among all racial and 
ethnic  groups  and  accounted  for  34.2%  (829,072)  of  all 
2,425,900 deaths in 2006, or 1 of every 2.9 deaths.2
In China, where the people account for one fifth of the 
world’s  population,  since  the  1950s,  the  mortality  of  CVD 
increased threefold as a percentage of total deaths, from 12% 
to 36%.3
In India, where the people account for one sixth of the 
world’s  population,  the  estimated  data  suggests  that  CVD 
accounts for 24% of total deaths.4
More seriously, a series of controllable CVD risk factors, 
including smoking, hypertension, fat consumption, high plasma 
cholesterol  levels,  physical  inactivity,  diabetes  mellitus  and 
obesity are spreading at an unprecedented speed all over the 
world.
CVD will dominate as the major cause of death by 2020, 
accounting for at least one in every three deaths all over the 
world.1
It’s estimated that by 2020, we could meet the pinnacle of 
CVD.1
CVD also presents a heavy burden to family and society, 
in terms of both medical costs and human suffering. In 2008 
alone, the estimated direct and indirect cost of CVD only in 
the United States was $448.5 billion, an alarming statistic under 
these severe economic circumstances.2
Establishing  a  comprehensive,  global,  preventive  and 
therapeutic  line  of  defense  against  CVD  spreading  all  over 
the world is a sacred duty for governments, doctors and basic 
research scientists in the field.
Further enhancement of basic and clinical CVD research 
is the critical responsibility incumbent on all of us, as diverse 
professionals in the field of CVD.Preface to the First Issue, JCDR
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Based on the issues described herein, a group of outstanding 
cardiologists, basic research scientists from China, India, United 
States  and  Japan  etc.  have  established  this  double-blinded, 
peer-reviewed,  international  professional  journal,  Journal  of 
Cardiovascular  Disease  Research  (JCDR)  under  the  strong 
support of the non-profit, medical magazine running and the 
experienced publisher, E-Manuscript.
JCDR  covers  basic  scientific  research  to  clinical  practice 
and  deals  with  all  areas  of  cardiovascular  disease.  JCDR 
publishes  articles  on  work  at  the  molecular,  subcellular, 
cellular, tissular, organic and systemic levels with an emphasis 
on the pathophysiological mechanisms of CVD, while JCDR 
appreciates articles related to prevention, clinical observation, 
medication, interventional therapy, cardiac surgery and nursing. 
Cardiovascular  research  scientists,  physicians,  surgeons, 
pharmacists, occupational therapists, health care professionals 
and other related experts in cardiovascular disease research field 
are the intended directors, actors and audiences of JCDR.
JCDR is a platform, a platform for international academic 
information exchange among professionals in the field of CVD 
community all over the world.
JCDR  is  a  platform,  a  platform  for  presentation  and 
participation of your clinical or basic research achievements.
JCDR  is  a  platform,  a  platform  for  revelation  of  your 
intellectual sparks.
It is my sincere hope that you will dedicate your spark of 
wisdom to this JCDR platform. Perhaps, your spark will ignite 
into  a  bright  and  sustaining  flame  to  illuminate  your  other 
colleagues.
With the New Year’s bell striking, here, on behalf of our 
editorial board, I am pleased to announce the launch of Journal 
of Cardiovascular Disease Research (JCDR), a new non-profit 
official journal published by E- Manuscript.
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